Andrew Hirsch - Feb 14, 2024 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
President & CEO, Director
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Stock symbol
CCCC
Transactions as of
Feb 14, 2024
Transactions value $
$0
Form type
4
Date filed
2/15/2024, 05:08 PM
Previous filing
Sep 19, 2023
Next filing
Feb 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Award $0 +103K +90.78% $0.00 217K Feb 14, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Award $0 +466K $0.00 466K Feb 14, 2024 Common Stock 466K $7.31 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025.
F2 The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024.